KRAS and cancer: AZ628 and BP-1-102 combination significantly inhibited the growth of KRAS-mutant cancer cells and tumors, whereas single agent only had slight inhibition ability, which is consistent to the report of previous study that RAF inhibitors show little efficacy in KRAS mutant cancers [22].